MiR-29a-3p negatively regulates circulating Tfh memory cells in patients with Graves' disease by targeting ICOS

Yingzhao Liu1, Xuehua Wang2, Wenkang Luan3

  • 1Department of Endocrinology, The Affiliated People's Hospital of Jiangsu University, Zhenjiang Medical School of Nanjing Medical University, Zhenjiang, 212002, China.

Immunologic Research
|November 2, 2022
PubMed

Insights

MicroRNAs (miRNAs) regulate gene expression and are implicated in autoimmune diseases like Graves' disease (GD). This study found that miR-29a-3p acts as a brake on circulating Tfh memory cells in GD patients, potentially impacting disease pathogenesis.

Area of Science:

  • Immunology
  • Molecular Biology
  • Genetics

Background:

  • MicroRNAs (miRNAs) are key regulators of gene expression involved in autoimmune diseases.
  • Follicular helper T (Tfh) cells are critical in Graves' disease (GD) pathogenesis.
  • Mechanisms controlling circulating Tfh memory cells in GD are not fully understood.

Purpose of the Study:

  • Investigate the role of miRNAs in circulating Tfh memory cells in GD patients.
  • Identify specific miRNAs and their targets involved in Tfh cell regulation in GD.

Main Methods:

  • Analyzed miRNA expression profiles using sequencing.
  • Quantified Tfh cell proportions and IL-21 levels.
  • Assessed inducible co-stimulator (ICOS) expression.
  • Performed luciferase assays to confirm miRNA-target interactions.

Main Results:

  • Circulating Tfh memory cells, IL-21, and ICOS expression were elevated in GD patients.
  • miR-29a-3p was downregulated in GD patients and inversely correlated with ICOS and Tfh cells.
  • miR-29a-3p directly targets and inhibits ICOS expression.
  • Overexpression of miR-29a-3p decreased Tfh cell proportion and correlated negatively with TRAb levels.

Conclusions:

  • miR-29a-3p acts as a post-transcriptional regulator, inhibiting Tfh memory cell responses in GD.
  • miR-29a-3p may play a significant role in the pathogenesis of Graves' disease.
  • This finding offers potential therapeutic targets for managing GD.